HERCULES, CA — May 14, 2012 — Bio-Rad Laboratories, Inc. announced today that it has introduced two iTaq Universal supermixes that are compatible with any real-time PCR instrument. These products deliver robust performance and enable users to obtain high-quality data across all real-time quantitative PCR (qPCR) applications,.
The two new iTaq Universal supermixes include the iTaq Universal SYBR® Green supermix and the iTaq Universal Probes supermix, both of which are 2x concentrated, ready-to-use reaction master mixes. Both supermixes are made with a proprietary optimized buffer formulation for maximum sensitivity, efficiency and reproducibility.
The term “Universal” refers to the broad instrument compatibility and the ability to tolerate a broad range of reaction and protocol conditions. The iTaq Unversial supermixes, which contain a blend of multiple passive reference dyes, are particularly useful for researchers using real-time PCR instruments that require ROX fluorescent dyes. Researchers will now be able to use a single supermix, eliminating the need to change reagents between experiments and instruments.
The SYBR® Green supermix is optimized for dye-based qPCR and contains SYBR® Green I dye whereas the Probes supermix is formulated for probe-based qPCR (simplex or duplex).
Key benefits of the iTaq Universal supermixes include:
- Broad dynamic range and sensitivity — offers accurate and sensitive detection of a broad range of targets in gene expression analysis and other real time applications
- Optimized buffer formulation — provides efficient amplification of genomic DNA templates and difficult amplicons
- Overcomes challenging duplex qPCR — enables detection of two gene targets, even with a great differential in copy number, in one reaction
- Antibody-mediated hot-start DNA polymerase — gives instant and complete polymerase activation in 30 seconds
Visit www.bio-rad.com/supermixes for more information about the iTaq Universal supermixes.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
312-997-2436 x 112